Back to News
Mar 2, 2026 8:01 AM

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective March 1, 2026, the company granted non-qualified stock options to purchase 50,050 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

The stock options have an exercise price of $0.5283 per share, which is equal to the closing price of the company's common stock on February 27, 2026. Each stock option has a ten-year term ...